As competition among biotech venture capitalists in China escalates, U.S. firms are altering their investment strategies. They are no longer passively waiting for biotech assets to emerge.
Instead, these firms are proactively engaging with upstream scientific pipelines, which may enhance their positioning in a rapidly evolving market.
This shift reflects a broader trend in the biotech sector, where early-stage investments could yield significant returns as the industry matures.